3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
8
Rhabdomyosarcoma
8
Wilms Tumor
7
Malignant mesenchymal tumor
5
Kidney Neoplasms
4
Rhabdomyosarcoma, Embryonal
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Rhabdomyosarcoma, Alveolar
2
Hydatidiform Mole
2
Gestational Trophoblastic Disease
2
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Sarcoma, Ewing
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleuropulmonary blastoma
1
Lymphoma
1
Liposarcoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hemangiosarcoma
1
Hemangiopericytoma, Malignant
1
Fibrosarcoma
1
Desmoplastic Small Round Cell Tumor
1
Choroid Plexus Neoplasms
1
Choriocarcinoma
1
Brain Neoplasms
1
Blast Crisis
1
Beckwith-Wiedemann Syndrome
1
Interventions
Vincristine
2
Ifosfamide
2
Etoposide
2
Doxorubicin
2
Cyclophosphamide
2
Busulfan
2
treosulfan
1
ganitumab
1
etoposide phosphate
1
Zoledronic Acid
1
Triptorelin Pamoate
1
Temozolomide
1
Radiosurgery
1
Radiation
1
Melphalan
1
Irinotecan
1
FANG vaccine
1
Diphosphonates
1
Dactinomycin
1
Cyproheptadine
1
Congresses as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Sarcoma, Ewing
×
Dactinomycin
×
Clear all
NCT02063022
2022-09-19
EW-1
Italian Sarcoma Group
Phase 3
Completed
278 enrolled